Table 4.

Lesion reduction in neoadjuvant chemotherapy subgroups

	n	No residual disease	Residual disease	p	χ2
IA-NAC+ RS	40	11 (27.5%)	29 (72.5%)	0.033	4.557
IV-NAC+ RS	63	7 (11.1%)	56 (88.9%)